Carnegie acted as joint global co-ordinator and joint bookrunner in the IPO of Cinlus Pharma on Nasdaq Stockholm.
Cinclus Pharma is a clinical stage pharmaceutical company focused on the development of the drug candidate linaprazan glurate, a new and innovative mode of action for the treatment of erosive gastroesophageal reflux disease (“eGERD”).